Bevacizumab

Essential medicine status

General description

Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits angiogenesis. It is used in the treatment of vascular eye diseases and in treatment protocols for some cancers.

INN	Bevacizumab
ATC codes	S01LA08 L01FG01
Medicine type	Biological agent
EML status history	First added in 2013 (TRS 985) for Age-related macular degeneration Application rejected in 2025 (TRS 1064) for Hepatocellular carcinoma of liver
Wikipedia	Bevacizumab
DrugBank	Bevacizumab

Recommendations

Section Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations

- Parenteral > Locoregional injections > Intravitreal: 25 mg per mL

Indications

Age-related macular degeneration

Section Immunomodulators

- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion

Indications

Hepatocellular carcinoma of liver